Valeant VRX reported first-quarter results that were largely in line with our expectations and we do not anticipate making any changes to our fair value estimate or moat rating. Revenue grew 25% and cash EPS grew 43% over the prior year, largely because of the integration of Medicis. The firm continues to see very strong performance in the emerging markets, and shows no signs of … Continue reading Valeant Reports In Line 1Q, Again Exceeds Synergy Targets